drugset / Trial / NCT07022483
Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.
Timeline
- Start
- 2025-09-30
- Primary completion
- 2032-03-23
- Completion
- 2032-03-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Carboplatin | Small molecule | 5 unknown | — |
| Comparator | Carboplatin | Small molecule | 6 unknown | — |
| Comparator | Paclitaxel | Small molecule | 175 mg/m2 | — |
| Subject | Trastuzumab deruxtecan | Monoclonal antibody | 5.4 mg/kg | Intravenous |